Global Immunology Drugs Market Size is estimated to grow at a 10.5% CAGR during the forecast period for 2025-2034.
The medical and biological research field known as Immunology Drugs focuses on the immune system. Autoimmune disorders develop when the immune system assaults the body that it is supposed to defend. People with autoimmune disorders have a deficiency in their immune system that prevents them from telling "self" molecules apart from "non-self" or "foreign" molecules. Numerous laboratory tests are available in Immunology Drugs to identify autoimmune disorders. The increased frequency of immunological illnesses brought on by environmental changes and changing lifestyles, as well as the increased awareness of immunological disease in both developed and developing nations, are the driving forces behind the market's expansion.
Some of the major market participants are continually emphasizing innovation and expanding their product lines to improve patient treatment outcomes. It is anticipated that this will expand even further during the projection period. There is a growing patient population with autoimmune illnesses as a result of many environmental variables such as stress, infection, exposure to hazardous chemicals, and nutritional components.
The worldwide Immunology Drugs industry is likely to experience growth restraints over the forecast period due to a lack of technological advancements and expensive treatment costs. Additionally, many negative effects are associated with these treatments, such as fever, irregular or pounding heartbeat, muscle aches, allergic reactions, infections, etc. Therefore, the aforementioned limitations and the stringent reimbursement practices in emerging countries hinder market expansion throughout the projection period.
The immunology drugs market is segmented on the basis of drug class, distribution channel, and disease indications. Based on drug class, the market is segmented into monoclonal antibodies, fusion proteins, immunosuppressants, polyclonal antibodies, and other drug classes. Based on distribution channel, the market is segmented as hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. Based on disease indications, the market is segmented as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, inflammatory bowel disease, and other disease indication.
During the projection period, the immunosuppressants segment is anticipated to expand at a faster rate. Leading market participants' intense focus on R&D to establish the rising number of regulatory approvals for these pharmaceuticals is credited with this segment's quick expansion. Additionally, immunosuppressants are becoming more widely used in developing countries because of their superior therapeutic efficacy, which contributes to their rapid growth rate. The main driver of immunosuppressants is the rise in autoimmune diseases such as multiple sclerosis, alopecia areata, and arthritis. An increase in organ transplant procedures like kidney and liver transplants due to the rise in cases of organ failure fuels the development of immunosuppressants.
In the forecast period, the market will be dominated by the segment for inflammatory bowel disease. Over the forecast period, market growth is anticipated to be fuelled by the increasing prevalence of Crohn's disease and ulcerative illness worldwide. The escalating rates of Crohn's disease and ulcerative colitis are caused by a number of factors, including immune system instability, environmental triggers, and genetic predisposition. Most people with Crohn's disease or ulcerative colitis have a family history of the condition. The market for treating inflammatory bowel illness is anticipated to develop as a result of this. Additionally, it is predicted that the market will rise in the next years due to the rising use of biologics for therapy and the availability of potent pipeline medications like upadacitinib, risankizumab, tofacitinib, ustekinumab, and others.
Due to the availability of superior reimbursement laws, the huge potential to invest substantial funds in creating Immunology Drugs treatments, and the advancement of technology, North America dominates the worldwide market for Immunology Drugs pharmaceuticals. The larger patient pool in the regions, rising economies, increased government activities and increased awareness all point to the growing demand for Immunology Drugs drugs. The United States now dominates the global market due to its well-developed healthcare infrastructure, higher prevalence of chronic illnesses, and higher rates of diagnosis and treatment among patient populations.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD XX Billion |
|
Revenue Forecast In 2034 |
USD XX Billion |
|
Growth Rate CAGR |
CAGR of 10.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn, and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Drug Class, Distribution Channel, Disease Indications |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Eli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer, Novartis, Astellas, Alector, ImmuNext, Merck sharp & Dohme Corp, and UCB S. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Immunology Drugs Market Snapshot
Chapter 4. Global Immunology Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. By Drug Class & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Class:
5.2.1. Monoclonal antibody
5.2.2. Fusion Proteins
5.2.3. Immunosuppressant
5.2.4. Polyclonal antibody
5.2.5. Other Drug Class
Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis
6.1. By Distribution Channel & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Distribution Channel:
6.2.1. Hospital Pharmacies
6.2.2. Retail Pharmacies
6.2.3. Online Pharmacies
6.2.4. Other Distribution Channel
Chapter 7. Market Segmentation 3: By Disease Indications Estimates & Trend Analysis
7.1. By Disease Indications & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Disease Indications:
7.2.1. Rheumatoid Arthritis
7.2.2. Psoriatic Arthritis
7.2.3. Plaque Psoriasis
7.2.4. Ankylosing Spondylitis
7.2.5. Inflammatory Bowel disease
7.2.6. Other disease Indication
Chapter 8. Immunology Drugs Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Immunology Drugs Market revenue (US$ Million) estimates and forecasts By Drug Class, 2021-2034
8.1.2. North America Immunology Drugs Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
8.1.3. North America Immunology Drugs Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
8.1.4. North America Immunology Drugs Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Immunology Drugs Market revenue (US$ Million) By Drug Class, 2021-2034
8.2.2. Europe Immunology Drugs Market revenue (US$ Million) By Distribution Channel, 2021-2034
8.2.3. Europe Immunology Drugs Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
8.2.4. Europe Immunology Drugs Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Immunology Drugs Market revenue (US$ Million) By Drug Class, 2021-2034
8.3.2. Asia Pacific Immunology Drugs Market revenue (US$ Million) By Distribution Channel, 2021-2034
8.3.3. Asia Pacific Immunology Drugs Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
8.3.4. Asia Pacific Immunology Drugs Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Immunology Drugs Market revenue (US$ Million) By Drug Class, 2021-2034
8.4.2. Latin America Immunology Drugs Market revenue (US$ Million) By Distribution Channel, 2021-2034
8.4.3. Latin America Immunology Drugs Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
8.4.4. Latin America Immunology Drugs Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Immunology Drugs Market revenue (US$ Million) By Drug Class, 2021-2034
8.5.2. Middle East & Africa Immunology Drugs Market revenue (US$ Million) By Distribution Channel, 2021-2034
8.5.3. Middle East & Africa Immunology Drugs Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
8.5.4. Middle East & Africa Immunology Drugs Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Eli Lilly and Company
9.2.2. AbbVie Inc
9.2.3. F.Hoffmann-La roche Ltd
9.2.4. Amgen Inc
9.2.5. Pfizer
9.2.6. Novartis
9.2.7. Astellas
9.2.8. Alector
9.2.9. ImmuNext
9.2.10. Merck sharp & Dohme Corp.
9.2.11. UCB SA
9.2.12. Other Prominent Players
By Drug Class:
By Distribution Channel
By Disease Indications
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
